Kevin Joseph Fitzgerald
CSO & EVP, Head of Research at Alnylam Pharmaceuticals · 68 reported transactions in 1 company · latest trade Feb 17, 2026
Their trades
Sold | Feb 17, 2026 | Feb 17, 2026 close $332.61 → Oct 26, 2026 close $227.66. S&P 500 +12.1% over the same days. | ||
Sold | Feb 13, 2026 | Feb 13, 2026 close $314.40 → Oct 26, 2026 close $227.66. S&P 500 +12.3% over the same days. | ||
Sold | Jan 13, 2026 | Jan 13, 2026 close $369.96 → Oct 26, 2026 close $227.66. S&P 500 +10.3% over the same days. | ||
Sold | Jan 13, 2026 | Jan 13, 2026 close $369.96 → Oct 26, 2026 close $227.66. S&P 500 +10.3% over the same days. | ||
Sold | Jan 13, 2026 | Jan 13, 2026 close $369.96 → Oct 26, 2026 close $227.66. S&P 500 +10.3% over the same days. | ||
Sold | Jan 13, 2026 | Jan 13, 2026 close $369.96 → Oct 26, 2026 close $227.66. S&P 500 +10.3% over the same days. | ||
Sold | Jan 13, 2026 | Jan 13, 2026 close $369.96 → Oct 26, 2026 close $227.66. S&P 500 +10.3% over the same days. | ||
Sold | Jan 13, 2026 | Jan 13, 2026 close $369.96 → Oct 26, 2026 close $227.66. S&P 500 +10.3% over the same days. |
$677.5K
Feb 17, 2026 close $332.61 → Oct 26, 2026 close $227.66. S&P 500 +12.1% over the same days.
$607.4K
Feb 13, 2026 close $314.40 → Oct 26, 2026 close $227.66. S&P 500 +12.3% over the same days.
$45.7K
Jan 13, 2026 close $369.96 → Oct 26, 2026 close $227.66. S&P 500 +10.3% over the same days.
$104.4K
Jan 13, 2026 close $369.96 → Oct 26, 2026 close $227.66. S&P 500 +10.3% over the same days.
$180.1K
Jan 13, 2026 close $369.96 → Oct 26, 2026 close $227.66. S&P 500 +10.3% over the same days.
$238.3K
Jan 13, 2026 close $369.96 → Oct 26, 2026 close $227.66. S&P 500 +10.3% over the same days.
$207.2K
Jan 13, 2026 close $369.96 → Oct 26, 2026 close $227.66. S&P 500 +10.3% over the same days.
$72.4K
Jan 13, 2026 close $369.96 → Oct 26, 2026 close $227.66. S&P 500 +10.3% over the same days.